Ambien Liver Function Impact: What Clinicians and Patients Need to Know About Zolpidem Hepatotoxicity

What the label says about zolpidem and the liver

The label's hepatic instruction concerns clearance rather than a liver-injury threshold: section 5.8 tells prescribers to avoid Ambien in patients with severe hepatic impairment [1], and the warnings list possible hepatic encephalopathy among reported events [1].

How the liver handles zolpidem

Zolpidem is absorbed quickly, with a Tmax of about 1.6 hours, and reaches a mean Cmax of 59 ng/mL after 5 mg and 121 ng/mL after 10 mg [1]. It is 92.5% protein bound, has an elimination half-life of about 2.5 hours (range 1.4 to 4.5), and is converted to inactive metabolites eliminated mainly by the kidney; nightly dosing does not cause accumulation [1]. Metabolism involves CYP3A, and the label notes that the effect of drugs that induce or inhibit other P450 enzymes on zolpidem exposure is not known [1]. An interaction study describes zolpidem as metabolized in part by P450-3A and by a number of other cytochromes [3].

What cirrhosis does to zolpidem levels

In patients with cirrhosis, mean Cmax is about twice that of normal subjects, AUC about five times higher, and mean terminal half-life about 9.9 hours instead of roughly 2.5 [1]. The label lists coadministration of drugs that increase zolpidem blood levels among the factors that raise the risk of next-day psychomotor impairment, including impaired driving [1].

The dose the label specifies for liver disease

• Mild to moderate hepatic impairment: 5 mg immediate-release zolpidem once daily [1], or 6.25 mg Ambien CR once daily [2].
• Severe hepatic impairment: both the Ambien and Ambien CR labels say to avoid use [1][2].
• The same 5 mg limit applies to elderly or debilitated patients on immediate-release zolpidem, and the Ambien CR label gives 6.25 mg [1][2].
• The Ambien label recommends an initial dose of 5 mg for women and 5 or 10 mg for men [1]. The Ambien CR label recommends 6.25 mg for women and 6.25 or 12.5 mg for men [2]. The immediate-release label says initial doses differ because zolpidem clearance is lower in women [1]. The FDA required the lower women's doses in January 2013 [4].
• The Ambien label sets a 10 mg daily maximum [1]; the Ambien CR label sets a 12.5 mg daily maximum [2]. Both specify one dose before bedtime with at least 7 to 8 hours before waking [1][2].

Age adds a second layer. After a 20 mg dose, elderly subjects had Cmax 50% higher, half-life 32% longer and AUC 64% higher than young adults [1], and the 2023 AGS Beers Criteria recommend avoiding zolpidem in older adults (strong recommendation, moderate-quality evidence), citing delirium, falls, fractures and crashes with minimal sleep benefit [5].

Interactions that raise or lower zolpidem exposure

Ketoconazole, a potent CYP3A4 inhibitor, raised zolpidem AUC by 70% and Cmax by 30%, and the label says to consider a lower zolpidem dose when a potent CYP3A4 inhibitor is given with it [1]. A crossover study of 12 volunteers given 5 mg zolpidem found apparent oral clearance fell from 422 to 250 mL/min with ketoconazole and half-life rose from 1.9 to 2.4 hours; itraconazole and fluconazole also reduced clearance but not significantly, and only ketoconazole enhanced the benzodiazepine-like effects [3]. The label records a 34% rise in AUC with itraconazole [1].

In the other direction, rifampin cut zolpidem AUC by 73%, Cmax by 58% and half-life by 36%, and the label says the combination is not recommended [1]. St. John's wort may also lower zolpidem levels and is not recommended with it [1].

Smaller signals the label records: sertraline raised zolpidem Cmax by 43% over 17 days in healthy women; fluoxetine lengthened half-life by 17% without an added psychomotor effect; fluvoxamine and ciprofloxacin are likely to increase exposure [1].

Alcohol, opioids and other sedatives

The label's interaction section is mostly about additive sedation rather than altered metabolism: benzodiazepines, opioids, tricyclic antidepressants and alcohol add to CNS depression and psychomotor impairment, and opioids add respiratory depression risk [1]. An additive effect of alcohol and oral zolpidem on psychomotor performance was demonstrated [1], and taking zolpidem with another sedative-hypnotic at bedtime or in the middle of the night is not recommended [1].

Non-drug treatment for chronic insomnia

For chronic insomnia, the American College of Physicians recommends cognitive behavioral therapy for insomnia as initial treatment for all adults (strong recommendation, moderate-quality evidence), with medication added through shared decision-making when CBT-I alone has not worked (weak recommendation, low-quality evidence) [6].